Headlines about RTI Surgical (NASDAQ:RTIX) have trended somewhat positive this week, Accern reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. RTI Surgical earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave media headlines about the medical equipment provider an impact score of 46.3600259716415 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
RTIX has been the topic of a number of research analyst reports. BidaskClub downgraded RTI Surgical from a “hold” rating to a “sell” rating in a report on Friday, April 20th. Craig Hallum raised RTI Surgical from a “hold” rating to a “buy” rating in a research report on Friday, March 2nd. Finally, Zacks Investment Research cut RTI Surgical from a “hold” rating to a “sell” rating in a research report on Tuesday, March 6th.
Shares of RTIX traded down $0.05 during mid-day trading on Wednesday, reaching $4.45. The company had a trading volume of 2,853 shares, compared to its average volume of 166,705. The company has a quick ratio of 1.53, a current ratio of 3.81 and a debt-to-equity ratio of 0.31. RTI Surgical has a 52 week low of $3.85 and a 52 week high of $6.00. The stock has a market cap of $285.42 million, a P/E ratio of 89.00, a P/E/G ratio of 3.00 and a beta of 1.59.
RTI Surgical (NASDAQ:RTIX) last issued its quarterly earnings results on Thursday, May 3rd. The medical equipment provider reported $0.01 EPS for the quarter, hitting analysts’ consensus estimates of $0.01. RTI Surgical had a return on equity of 2.49% and a net margin of 2.57%. The firm had revenue of $69.89 million for the quarter, compared to analysts’ expectations of $68.70 million. equities analysts anticipate that RTI Surgical will post 0.1 EPS for the current year.
About RTI Surgical
RTI Surgical, Inc, together with its subsidiaries, designs, develops, manufactures, and distributes biologic, metal, and synthetic implants worldwide. It processes donated human musculoskeletal and other tissues, as well as bovine and porcine animal tissues to produce allograft and xenograft implants by using its proprietary BIOCLEANSE, TUTOPLAST, and CANCELLE SP sterilization processes.
Receive News & Ratings for RTI Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RTI Surgical and related companies with MarketBeat.com's FREE daily email newsletter.